DuPont de Nemours, Inc.

Under a severe cyclical stress test combining persistent European manufacturing stagnation, extended Asian industrial destocking, and unrecovered hydrocarbon inflation, DuPont's operating EBIT margin compresses to 10.5% while organic revenue growth turns negative at -0.36%. In this scenario, free cash flow generation contracts toward maintenance capital expenditure requirements, eliminating capacity for discretionary share repurchases and straining debt coverage on $3,194M in total debt. Intrinsic fair value contracts to $71.51, representing a 45.0% decline from the October 9, 2026 share price of $130.00.

Narrow

DuPont possesses a narrow economic moat grounded in customer switching costs and proprietary formulation intangibles within its specialty materials portfolio. In Healthcare & Water Technologies, which generated $3,233M in FY2025 revenue, proprietary membrane chemistries (FilmTec) and medical barrier packaging (Tyvek) are deeply embedded in customer production processes. Biopharmaceutical packaging and municipal desalination facilities undergo lengthy validation and regulatory certification cycles, making supplier substitution costly and operationally disruptive. These dynamics support management's guidance of mid-single-digit organic growth for the segment in 2H 2026.

Conversely, the Diversified Industrials segment, representing $3,616M in FY2025 revenue, faces more cyclical end-market exposure across automotive, aerospace, and general industrial accounts. While aramid fibers (Kevlar, Nomex) maintain premium technical positioning, customer switching barriers are lower than in healthcare. Management has focused on the 80/20 operating model to prioritize high-margin product lines and implemented $90M in annual pricing surcharges. However, this pricing is limited to dollar neutrality against hydrocarbon inflation rather than percentage margin expansion.

DuPont's structural moat is evaluated as narrow rather than wide because of peer competitive dynamics and capital intensity. Competitors such as Ecolab generate superior operating margins of 18.52%, compared to the broader chemical industry operating margin benchmark of 12.4%. DuPont's normalized ROIC of 4.04% remains below its computed WACC of 8.82%, reflecting legacy goodwill and past restructuring costs. Although moat-protected segments provide defensive cash flow, broader cyclical industrial exposure caps economic profit expansion over the medium term.

DuPont de Nemours Inc. (DD) trades at 16.5x forward earnings against a peer median of 22.5x. Its EV/EBITDA of 12.3x compares with a peer median of 16.9x. The comparison uses 4 peers: International Flavors & Fragrances Inc., PPG Industries Inc., The Sherwin-Williams Company and Ecolab Inc., as of 2026-10-11.

DuPont de Nemours Inc. (DD) is rated Sell. While the company's operational execution is stabilizing—with management raising FY2026 adjusted EPS guidance to $7.24 and free cash flow conversion tracking near 100% —the stock's market price of $130.00 sits at a 29.86% premium over our composite intrinsic fair value of $100.11. Even the optimistic bull case ($128.56) falls below current trading levels, leaving investors with negative risk-adjusted expected return.^4,5

Fundamental valuation models synthesize forward earnings ($105.16, 40% weight), multi-stage moat fade ($126.18, 35% weight), and enterprise DCF ($55.53, 25% weight). The heavy debt burden of $3,194M and dollar-neutral pricing limitations anchor fundamental value well below sell-side consensus targets. Investors should liquidate positions and redeploy proceeds into opportunities with compelling valuation upside.